Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 in metastatic breast and endometrial cancer
NCT03394027Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2018
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dordaviprone in Hormone-Receptor-Positive Breast Cancer, triple negative breast cancer (TNBC) and endometrial cancer (EC), sponsored by National Cancer Institute. Primary endpoints: Progression-Free Survival (Cohort 1) at 8 months, Overall Response Rate (Cohort 2) and 1 more. Started Jan 2018; status: completed.
02
Drugs
dordaviprone
03
Conditions
Hormone-Receptor-Positive Breast Cancertriple negative breast cancer (TNBC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03394027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394027.